685570-92-7

Upstream product

• 20180-08-9 (R,S)-Diethyl-(2-hydroxypropyl)phosphonat 
• 172966-53-9 (S)-N-{3-[3-fluoro-4-(4-oxo-piperidin-1-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide 

Downstream Products

• 685570-93-8 N-[[(5S)-3-[3-fluoro-4-(4-(2-acetoxy-propylidene)-piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]-acetamide 
• 685570-95-0 N-[[(5S)-3-[3-fluoro-4-(4-(2-(dichloroacetoxy)-propylidene)-piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]-acetamide 
• 685570-94-9 N-[[(5S)-3-[3-fluoro-4-(4-(2-(chloroacetoxy)-propylidene)-piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]-acetamide 
• 685571-16-8 N-[[(5S)-3-[3-fluoro-4-(4-(2-hydroxy-propylidene)-piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]-acetamide hydrochloride salt 

Relevant academic research and scientific papers

Synthesis and in vitro activity of new methylenepiperidinyl and methylenepyrrolidinyl oxazolidinone antibacterial agents

We have prepared and evaluated the antibacterial activities of a series of substituted methylenepiperidinyl and methylenepyrrolidinyl oxazolidinones against several gram-positive strains including the resistant strains of Staphyloccus and Enterococcus, such as MRSA, CRSA, MSSA and VRE. Some of them showed comparable or superior in vitro activities (MIC) to vancomycin.